Related Experiment Video

Updated: Jul 18, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Inhibitors Targeting the F-BOX Proteins

Yalnaz Naseem1,2,3,4,5, Chaofeng Zhang1,2,3,4,5, Xinyi Zhou1,2,3,4,5

  • 1School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.

Cell Biochemistry and Biophysics
|August 25, 2023
PubMed

Insights

F-box proteins regulate cell processes via ubiquitylation; mutations cause malformations. Inhibitors targeting F-box proteins show promise for novel cancer therapies by inducing apoptosis in cancer cells.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Oncology

Background:

  • F-box proteins mediate substrate ubiquitylation and degradation, crucial for cellular processes.
  • Dysregulation of F-box protein activity is linked to human malformations and cancer development.
  • Targeting F-box proteins offers a potential therapeutic strategy for various cancers.

Purpose of the Study:

  • To explore the role of F-box proteins in malignancy.
  • To review F-box inhibitors and their therapeutic potential in cancer treatment.
  • To identify promising anti-cancer strategies targeting F-box proteins and associated pathways.

Main Methods:

  • Literature review of key studies on F-box protein function and cancer.
  • Analysis of F-box protein-mediated proteolysis in cellular processes.
  • Investigation of F-box inhibitors, including NVD-BK M120, and their mechanisms.

Main Results:

  • F-box proteins are implicated in cell proliferation, apoptosis, invasion, angiogenesis, and metastasis.
  • NVD-BK M120, an FBW7 inhibitor, induces apoptosis in lung cancer cells by affecting MCL1 levels.
  • F-box inhibitors demonstrate efficacy against specific mutated proteins in certain cancers.

Conclusions:

  • F-box proteins play a critical role in cancer development and progression.
  • Targeted inhibition of F-box proteins represents a promising avenue for developing novel anti-cancer therapies.
  • Further research into F-box protein pathways can lead to more effective cancer treatments.
Keywords:
E3 ligaseF-box proteinUbiquitincancer progressionsmall molecule inhibitorsubstrate

More Related Videos

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

9.2K
Determination of Tripartite Interaction between Two Monomers of a MADS-box Transcription Factor and a Calcium Sensor Protein by BiFC-FRET-FLIM Assay14:34

Determination of Tripartite Interaction between Two Monomers of a MADS-box Transcription Factor and a Calcium Sensor Protein by BiFC-FRET-FLIM Assay

Published on: December 25, 2021

3.8K

Related Concept Videos

Protein Complexes with Interchangeable Parts01:57

Protein Complexes with Interchangeable Parts

Groups of proteins may form a complex where each protein in this complex has a different role in the overall execution of the complex’s function. Often some of the proteins in the complex can be replaced by a closely related variant to give a complex that contains many of the same components yet is functionally distinct.
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
2.6K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
9.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K